Prosecution Insights
Last updated: November 20, 2026
Application No. 17/630,965

METHOD OF MAKING GLYCEROL CARBONATE (METH)ACRYLATE AND CURABLE COMPOSITIONS BASED THEREON

Non-Final OA §103
Filed
Jan 28, 2022
Priority
Jul 31, 2019 — provisional 62/880,864 +1 more
Examiner
MCCLENDON, SANZA L
Art Unit
1765
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Arkema France
OA Round
3 (Non-Final)
80%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
91%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allowance Rate
1010 granted / 1256 resolved
+15.4% vs TC avg
Moderate +11% lift
Without
With
+10.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
29 currently pending
Career history
1291
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
40.6%
+0.6% vs TC avg
§102
28.3%
-11.7% vs TC avg
§112
17.9%
-22.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1256 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicants’ submission filed on 17 September 2026 has been entered. Response to Amendment In response to the Amendment received on 17 September 2026, the examiner has carefully considered the amendments. The examiner acknowledges the cancellation of claim 16. The claim rejection under 35 U.S.C. § 112, 2nd paragraph for claim 16 is moot in view of the amendment and has hereby been withdrawn from consideration. Response to Arguments Applicants’ arguments filed, 17 September 2026 have been fully considered but they are not persuasive. Applicants appear to be relying on the amendment to overcome the rejection. Applicant, referring to example #6 cited in the previous action, argues that two separate changes are needed to reach the instant composition: (1) replacing NVP with a vinyl ester and (2) separately replacing RX03593 with a methacrylate-functionalized monomer. As previously set forth, Miller (paragraph 129) lists numerous monomers including (meth)acrylate (i.e. methacrylates or acrylates), vinyl pyrrolidone, vinylester etc. as diluent monomers in the composition. It would have been prima facie obvious to substitute the cited example's the RX03593 unidentified acrylate monomer with a methacrylate monomer as Miller considers these diluents as equivalent for the purpose of viscosity/rheology adjustment. A skilled artisan, from the overall teachings, would understand Miller by definition sets forth both (meth) acrylate and acrylate monomers—see [0052] teaches (meth) acrylate monomers, i.e., acrylate and methacrylate and formulas in [0140] where R1 is defined as H or CH3, i.e., acrylate or methacrylate. Additionally, it is known in the art that the addition of methacrylic monomers in combination with acrylate monomers in radiation curable composition increases the adhesion to polycarbonate polymeric substrates and stainless-steel substrates, as evidenced by Tumey. Tumey sets forth radiation curable adhesive comprising a monomeric acrylic or methacrylic acid ester, a copolymerizable reinforcing monomer, a copolymerizing macromonomer and a photoinitiator. Per example 18-19, Tumey shows the addition of methacrylate monomers in acrylic syrups shows static shear values of greater than 10,000 minutes on stainless steel, as well as, having superior adhesion build as compared to the compositions of the Comparative Examples comprising acrylate monomers in acrylic syrups. Therefore, it would have been within the skill level of an ordinary, from the overall teachings, to choose as a methacrylate monomer, as well as, obtain a composition such as found in example 6 to use a methacrylated version of RX03593 with a reasonable expectation of successfully obtaining a curable composition have high flexibility, high adhesion to polymeric substrates, low post-cure surface tackiness, and low shrinkage upon cure [0007] in absence of evidence to the contrary. Therefore, the rejection still stands. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 12-15 rejected under 35 U.S.C. 103 as being unpatentable over Miller 2004/0152799. Miller exemplifies (6) a UV polymerizable composition of 40.76 parts RX04918, 19.88 parts RX03593, 24.85 parts RD RX/201, 4.97 parts NVP, 4.97 parts Ebecryl7100, 0.6 parts TEGO and 3.98 parts Darocur 1173. RD RX/201(paragraph 215) is glycerol carbonate methacrylate and is present at ~25wt%. RX04918 (paragraph 191) is a urethane acrylate which qualifies as applicant’s oligomer. NVP (paragraph 216) is vinylpyrrolidone. RX03593 (paragraph 205) is an unidentified acrylate monomer. Ebecryl7100 (paragraph 207) is an amine functional acrylate. This example lacks one of applicants’ Markush lists of monomers and a methacrylate other than the glycerol carbonate methacrylate. However, Miller (paragraph 129) lists numerous monomers including (meth)acrylate (i.e. methacrylates or acrylates), vinyl pyrrolidone, vinylester etc. as diluent monomers in the composition. It would have been prima facie obvious to substitute the cited example’s vinyl pyrrolidone with a vinylester and the RX03593 unidentified acrylate monomer with a methacrylate monomer as Miller considers these diluents as equivalent for the purpose of viscosity/rheology adjustment. In regard to applicant’s dependent claims: RX04918’s urethane acrylate has a molecular weight of 4,475 (paragraph 191). This is well within applicant’s 500-50,000 range (page 12 line 15 of spec). Furthermore, urethane acrylates such as NeoRad U-60 of Mw 4,500 have a viscosity of 27,000-37,000mPa.s (see page 4 of the Covestro brochure). For these reasons it is believed that inherently, RX04918 has a viscosity above 10,000cps. When this oligomer is combined with the glycerol carbonate methacrylate and additional diluent monomers in a ~40/60 ratio, presumably the viscosity would be significantly reduced below 10,000cps as in applicant’s example 19 which meets applicant’s claim 14. Presumably the reference’s mixture of 40.76% urethane acrylate with 24.85% glycerol methacrylate meets applicant’s claim 15 requirements as the 24.85% glycerol carbonate methacrylate is well above applicant’s minimum of 1% (page 10 line 1 of spec) and above applicant’s amount of example 16. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SANZA L MCCLENDON whose telephone number is (571)272-1074. The examiner can normally be reached 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heidi Riviere-Kelley can be reached at 571-270-1831. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SANZA L. McCLENDON/Primary Examiner, Art Unit 1765 SMc
Read full office action

Prosecution Timeline

Jan 28, 2022
Application Filed
Aug 22, 2025
Non-Final Rejection mailed — §103
Feb 23, 2026
Response Filed
Mar 17, 2026
Final Rejection mailed — §103
Sep 17, 2026
Request for Continued Examination
Oct 05, 2026
Response after Non-Final Action
Oct 28, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799348
PHOTONIC LACQUERING OF WIRES
3y 5m to grant Granted Nov 17, 2026
Patent 12799257
Block Copolymer Composition And Methods Of Preparation Thereof
3y 1m to grant Granted Nov 17, 2026
Patent 12779750
ROLLER, IN PARTICULAR FOR A SLIDING DOOR
3y 10m to grant Granted Nov 03, 2026
Patent 12781042
BIO-BASED THERMOFORMED PACKAGING AND METHODS OF FORMING THE SAME
3y 8m to grant Granted Nov 03, 2026
Patent 12780971
CURABLE RESIN COMPOSITION FOR DECORATION FILM, DECORATION FILM AND MOLDED DECORATION FILM ARTICLE
3y 4m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
80%
Grant Probability
91%
With Interview (+10.7%)
2y 9m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1256 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month